What are NeoGenomics's total assets?

NeoGenomics (NEO) holds $1.3B in total assets, down 15.9% year over year.

How much debt does NeoGenomics have?

NeoGenomics carries $66.3M in total debt against $828.8M of shareholders' equity, a debt-to-equity ratio of 0.08.

How much cash does NeoGenomics have?

NeoGenomics holds $146.1M in cash and equivalents.

Can NeoGenomics cover its short-term obligations?

Its current ratio is 4.42 — current assets exceed current liabilities.

Where does NeoGenomics's balance sheet data come from?

Every line is extracted from NeoGenomics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

NeoGenomics NEO Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$159.62M-56.5%	$367.01M+7.2%	$342.49M+30.1%	$263.18M-16.9%
Accounts receivable, net	$159.24M+5.8%	$150.54M+14.7%	$131.23M+9.6%	$119.71M+6.8%
Inventories	$28.57M+6.8%	$26.75M+10.7%	$24.16M-0.5%	$24.28M+3.8%
Prepaid expenses and other current assets	$138K-99.3%	$20.17M+12.1%	$17.99M+18.0%	$15.24M+23.3%
Total current assets	$376.29M-36.9%	$596.02M-0.1%	$596.81M-1.4%	$605.29M-11.2%
Property and equipment, net	$84.83M-9.8%	$94.1M+2.3%	$92.01M-10.2%	$102.5M-6.4%
Accumulated depreciation	$209.06M+10.0%	$189.99M—	——	——
Operating lease right-of-use assets	$78.44M-1.4%	$79.58M-13.3%	$91.77M-4.5%	$96.11M-6.0%
Goodwill	$524.34M+0.3%	$522.77M0.0%	$522.77M0.0%	$522.77M-0.8%
Intangible assets, net	$286.53M-15.6%	$339.68M-9.0%	$373.13M-8.6%	$408.26M-7.7%
Deferred tax assets	$18.22M-15.3%	$21.51M-11.4%	$24.29M-30.1%	$34.75M-37.4%
Other non-current assets	$36K-99.4%	$5.89M+24.1%	$4.74M-7.2%	$5.11M-28.7%
Total noncurrent assets	$983.54M-5.6%	$1.04B-3.9%	$1.08B-4.4%	$1.13B-4.5%
Total assets	$1.36B-17.0%	$1.64B-2.6%	$1.68B-3.4%	$1.74B-6.9%
Accounts payable	$23.09M+6.9%	$21.61M+6.3%	$20.33M-0.9%	$20.51M+14.4%
Accrued expenses	$47.58M-23.8%	$62.44M+17.5%	$53.16M+32.4%	$40.14M+4.8%
Deferred revenue	$851K+108%	$409K-80.8%	$2.13M-71.8%	$7.56M+45.6%
Operating lease liabilities, current	$4.78M+41.3%	$3.38M-39.7%	$5.61M-14.8%	$6.58M-4.4%
Contract liabilities	$386K+14.9%	$336K—	——	——
Accrued interest	$500K-61.5%	$1.3M—	——	——
Total current liabilities	$88.3M-70.7%	$301.24M+213%	$96.3M+7.1%	$89.93M+3.1%
Operating lease liabilities, non-current	$62.82M+3.3%	$60.84M-10.4%	$67.87M-1.6%	$68.95M-4.6%
Other non-current liabilities	$12.07M+2.5%	$11.77M-9.7%	$13.03M-0.2%	$13.06M-6.9%
Total noncurrent liabilities	$434.97M+0.1%	$434.46M-32.5%	$643.39M-1.3%	$652.08M-3.3%
Total liabilities	$523.27M-28.9%	$735.7M-0.5%	$739.69M-0.3%	$742.01M-2.6%
Common stock	$129K+0.8%	$128K+0.8%	$127K0.0%	$127K+2.4%
Additional paid-in capital	$1.27B+3.4%	$1.23B+3.2%	$1.19B+2.5%	$1.16B+3.3%
Retained earnings	-$433.81M-33.2%	-$325.78M-31.9%	-$247.06M-55.3%	-$159.09M-972%
Accumulated other comprehensive income (loss)	$4K+102%	-$206K+87.7%	-$1.67M+57.1%	-$3.9M-511%
Total stockholders' equity	$836.56M-7.3%	$902.34M-4.2%	$941.54M-5.7%	$998.02M-9.9%
Total liabilities and stockholders' equity	$1.36B-17.0%	$1.64B-2.6%	$1.68B-3.4%	$1.74B-6.9%
Capitalized Contract Costs, Current	$138K-33.0%	$206K—	——	——
Deferred costs	$138K-33.0%	$206K—	——	——
Other current assets	$7.42M-36.7%	$11.72M+42.3%	$8.24M+2.0%	$8.08M-1.4%
Capitalized Contract Costs, Net	$174K-19.8%	$217K—	——	——
Deferred Tax Assets and Other Non-Current Assets	$9.39M+59.6%	$5.89M+24.1%	$4.74M-7.2%	$5.11M-28.7%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Intangible Assets Gross (Excluding Goodwill)	$467.42M-6.3%	$498.8M—	——	——
Net Investment in Lease	$78.44M-1.4%	$79.58M-13.3%	$91.77M-4.5%	$96.11M-6.0%
Deferred costs	$36K+227%	$11K—	——	——
Intangible assets — net	——	——	——	——
Other intangible assets—net	$286.53M-15.6%	$339.68M-9.0%	$373.13M-8.6%	$408.26M-7.7%
Operating lease right-of-use assets	$78.44M-1.4%	$79.58M-13.3%	$91.77M-4.5%	$96.11M-6.0%
Other non-current assets	$9.39M+59.6%	$5.89M+24.1%	$4.74M-7.2%	$5.11M-28.7%
Operating Lease Right-of-Use Assets in Other Assets	$78.44M-1.4%	$79.58M-13.3%	$91.77M-4.5%	$96.11M-6.0%
Software and Technology Licenses, Net	$9.39M+59.6%	$5.89M+24.1%	$4.74M-7.2%	$5.11M-28.7%
Accrued Manufacturing Costs	$47.58M-23.8%	$62.44M+17.5%	$53.16M+32.4%	$40.14M+4.8%
Accrued Progress Collections and Price Adjustments	$386K+14.9%	$336K—	——	——
Compensation and benefits	$47.58M-23.8%	$62.44M+17.5%	$53.16M+32.4%	$40.14M+4.8%
Self-Insurance Reserve	——	——	——	——
Contract Liabilities, Non-Current	$386K+14.9%	$336K—	——	——
Convertible Debt (Non-Current)	$341.86M+0.4%	$340.34M-36.8%	$538.2M+0.5%	$535.32M+0.5%
Accrued expenses and other liabilities	$12M-4.9%	$12.62M-16.2%	$15.07M0.0%	$15.07M-15.3%
Deferred revenue, net of current portion	$386K+14.9%	$336K—	——	——
Total debt	$67.6M-74.5%	$265M+261%	$73.48M-2.8%	$75.61M-5.9%
Common Stock Par Value Per Share	$0.000.0%	$0.00—	——	——
Common Stock Shares Issued	129M+0.7%	128.1M—	——	——
Additional paid-in capital	$1.27B+3.4%	$1.23B+3.2%	$1.19B+2.5%	$1.16B+3.3%
Number of Exercisable Options	——	——	——	——
Number of Vested and Expected to Vest Options	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	7.2M+36.9%	5.2M—	——	——
Weighted Average Exercise Price of Outstanding Options	$13.58-15.9%	$16.14—	——	——
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$0—	——	——
Common stock, shares authorized (in shares)	$250M0.0%	$250M—	——	——
Common stock, shares issued (in shares)	$128.99M+0.7%	$128.15M—	——	——
Common Stock, Shares, Outstanding	$128.99M+0.7%	$128.15M—	——	——
Contract with Customer, Liability	$1.24M+66.0%	$745K—	——	——
Convertible debentures	$341.86M+0.4%	$340.34M-36.8%	$538.2M+0.5%	$535.32M+0.5%
Cost	——	$20.11M—	——	——
Deferred income taxes	$18.22M-15.3%	$21.51M-11.4%	$24.29M-30.1%	$34.75M-37.4%
Thereafter	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$180.89M+13.7%	$159.12M—	——	——
2028	——	——	——	——
2030	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Indefinite- lived intangible impairment	$467.42M-6.3%	$498.8M—	——	——
Prepaid expenses	$21.44M+6.3%	$20.17M+12.1%	$17.99M+18.0%	$15.24M+23.3%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$7.16M+36.9%	$5.23M—	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$13.58-15.9%	$16.14—	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about NeoGenomics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are NeoGenomics's total assets?: NeoGenomics (NEO) holds $1.3B in total assets, down 15.9% year over year.
How much debt does NeoGenomics have?: NeoGenomics carries $66.3M in total debt against $828.8M of shareholders' equity, a debt-to-equity ratio of 0.08.
How much cash does NeoGenomics have?: NeoGenomics holds $146.1M in cash and equivalents.
Can NeoGenomics cover its short-term obligations?: Its current ratio is 4.42 — current assets exceed current liabilities.
Where does NeoGenomics's balance sheet data come from?: Every line is extracted from NeoGenomics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.